Indications

This product is applicable to the thrombolytic therapy for an adult who suffers acute myocardial infarction caused by coronary artery occlusion. It helps to improve the ventricular function of a patient who has just suffered myocardial infarction. 

Highlights

1. Reteplase is the third generation thrombolytic drug, compared with Activase (Alteplase) from Boehringer Ingelheim GmbH, the second generation thrombolytic drug.

2. Reteplase has the advantages below:

    More convenient administration 

    Less dosage

    Less adverse reaction

Dosage Form

Freeze-dried powder for injection

Specification 

18mg/10ml/vial